Friday, September 2, 2011
MorphoSys AG, of Martinsried, Germany, said it dosed the first patient in a Phase I/IIa trial testing the safety and preliminary efficacy of anti-CD38 cancer antibody MOR202 in patients with relapsed or refractory multiple myeloma. The study is expected to enroll a maximum of 82 patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.